Top Industry Leaders in the Celiac Disease Treatment Market
Latest Celiac Disease Treatment Companies Update:
Chugai Pharmaceutical Published promising results from a non-clinical study on DONQ52, a medication targeting the immune response to gluten without affecting the whole immune system. A phase 1 clinical trial is ongoing.
Topas Therapeutics Their phase 2a clinical trial for TPM502, an antigen-specific nanoparticle therapy for celiac disease, is underway. This therapy aims to induce immune tolerance towards gluten.
Alnylam Pharmaceuticals Announced positive preliminary results from a phase 1b study of lumasiran for celiac disease. Lumasiran targets a specific gene involved in the immune response to gluten.
ImmusanT This clinical-stage biotech company is developing ITM-15, a potential first-in-class T-cell therapy for celiac disease. They announced the initiation of a phase 1b/2a clinical trial in December 2023.
List of Celiac Disease Treatment Key companies in the market
-
General Mills Inc.
-
Innovate Biopharmaceutical
-
ActoBio
-
Glenmark Pharmaceuticals Company Ltd.
-
Takeda Pharmaceuticals Company Ltd.
-
Zydus Pharmaceuticals Inc.
-
BioLineRx
-
West-Ward Pharmaceuticals Company Ltd.
-
Calypso Biotech SA